Genetically modified nk cell line transduced with gene encoding novel chimeric antigen receptor and use thereof
OwnerYoung Chul SUNG, Sae Won KIM +1inventors
InventorsYoung Chul SUNG, Sae Won KIM, Injung HWANG
Life of this patent
Estimating the term…
Abstract
The present invention provides a genetically modified NK cell line prepared by transducing host NK cell line with a gene construction encoding a cancer antigen-specific chimeric antigen receptor (CAR) comprising a FLT3-specific monoclonal antibody or a functional fragment thereof, a transmembrane domain, and a CD3ζ domain of a T-cell receptor for more efficient immunotherapy of acute myeloid leukemia, and use thereof, for more efficient immunotherapy of acute myeloid leukemia.
Claims35
A genetically modified NK cell line expressing a FLT3-specific chimeric antigen receptor by transducing an isolated NK cell line having the following characteristic with a polynucleotide encoding an FLT3-specific chimeric antigen receptor:
- positive for CD2, CD7, CD11a, CD25, CD28, CD45, CD54, DNAM-1, CD62L and CD56;
- and
- negative for CD1a, CD3, CD4, CD8, CD14, CD20, CD23, CD34, TCRαβ and TCRγδ.
A method for treating cancer in an individual in need of cancer treatment, comprising administering a therapeutically effective amount of the genetically modified NK cell line and optionally a suicide inducing agent to the individual.
Dependencies are inferred from the claim text.